Fluconazole is a triazole broad-spectrum antifungal drug that inhibits the reproduction and growth of fungi by highly selectively inhibiting the C-14-alpha;-demethylation of fungal cytochrome P-450 sterols, causing the accumulation of 14-alpha;-methyl sterols in fungi. In vitro tests have shown that this product has antibacterial activity against Cryptococcus neoformans and Candida species. Oral and intravenous injection of fluconazole in animals is effective in the following animal fungal infection models: Candida infection (including systemic candidiasis in immunodeficient animals); Cryptococcus neoformans infection (including intracranial infection); Microsporum and Trichophyton infection, etc. Fluconazole is also effective against Blastomyces dermatitidis infection and Coccidioides immitis infection (including intracranial infection); and is also effective against infections caused by Histoplasma capsulatum in normal animals and immunosuppressed animals.

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and has strong antibacterial activity against most Enterobacteriaceae (such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, gonococci, etc.); it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

This product is a brain metabolism improving drug, which is a cyclic derivative of г-aminobutyric acid. It has the effect of resisting brain function damage caused by physical and chemical factors. It can promote the generation of ATP in the brain, promote the synthesis of acetylcholine and enhance the conduction of nerve excitement, and has the effect of promoting brain metabolism. It can resist brain function damage caused by physical and chemical factors. It has an improving effect on retrograde amnesia caused by hypoxia. It can enhance memory and improve learning ability.

According to the requirements of the "Non-clinical Research Management Standards for Drugs", this product has been tested on mice, guinea pigs and cats. The results show that: mice had no abnormal toxic reactions within 48 hours after injection of 0.8ml/mouse; the results of the antihypertensive substance test for cats met the requirements of the pharmacopoeia; guinea pigs had no effect on activity, food intake, water intake and weight gain after intraperitoneal injection, and the incidence rate of allergic reactions and mortality were 0; ICR mice had no abnormal reactions and no animal deaths after intravenous injection of 100ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.